New insulin copycat could slash diabetes costs
NCT ID NCT07560150
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study compares a new rapid-acting insulin (I004) to the approved NovoLog in 60 healthy adults. Researchers measure how fast the insulin enters the blood and how well it controls blood sugar using a special clamp technique. The goal is to show the two insulins work the same, which could lead to a cheaper option for diabetes management.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Insulin aspart (rapid-acting insulin)
- What this could lead to
- If successful, this could provide a more affordable alternative to NovoLog for managing blood sugar in people with diabetes.
- What could go wrong
- This is an early-stage biosimilar study in healthy volunteers, not people with diabetes. It only measures short-term effects, so it may not predict real-world outcomes or long-term safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULIN ASPART are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amphastar Study Site
Chula Vista, California, 91911, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- First human trial launches for Hemay5259: a new Extended-Release drug candidate
- Apples' hidden power: study probes how polyphenols scavenge harmful carbonyls
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- New painkiller injection could cut opioid use after chest surgery